Table 1. Characteristics of studies included in the present meta analysis.
| Author | Country | Method | Number | Mean | Male | HR | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Language | Cut-off value | Studytime | Positiverate | Age range | Female | Tumorstage | Follow-upperiod | 95%CI | P value | NOS score |
| Hironoet al 1995 | Japan English | IHC≥1+ | 1983-1990 | 10339.8% | NR | NR | stage II–IV | NR | 1.15(0.65-2.06) | 0.631 | 6 |
| Jonjicet al 1997 | Italy English | IHC≥1+ | 1987-1989 | 5653.6% | 70(40-87) | 31/25 | stage I–IV | NR | 2.33(1.25-4.36) | 0.008 | 7 |
| Songet al 2004 | Korea English | IHC≥10% | 1996-2001 | 73925.4% | 59(19-80) | 495/244 | stage I–III | 31(1-97) | 0.99(0.56-1.73) | 0.972 | 8 |
| Langeret al 2006 | Germany English | IHC≥10% | 1991-2002 | 13755% | 63(33-83) | 125/12 | stage I–III | 36 | 1.01(1-1.02) | 0.039 | 7 |
| Galiziaet al 2007 | Italy English | IHC≥1% | 1996-2005 | 8244% | 62(34-83) | 51/31 | stage I–IV | 49(6-12) | 2.97(1.22-7.22) | 0.017 | 7 |
| Matsubaraet al 2008 | Japan English | IHC≥10% | 1997-2004 | 8763% | 64 | 70/17 | un-resectable or recurrent | NR | 0.99(0.63-1.57) | 0.97 | 7 |
| Kimet al 2008 | Korea English | IHC≥2+ | 1999 | 51127.4% | 55.4 | NR | stage I–IV | 68(1-108) | 1.84(1.35-2.49) | 0.001 | 7 |
| Kimet al 2009 | Korea English | IHC≥1+ | 1995-2003 | 15380.7% | 52(15-72) | 108/45 | stage III–IV | 72.9(2-135) | 0.605(0.37-0.99) | 0.045 | 8 |
| Czyzewskaet al 2009 | Poland English | IHC≥50% | 1996-1998 | 5554.5% | 60(30-78) | 17/38 | stage I–IV | 84 | 1.09(0.53-2.25) | 0.815 | 7 |
| Inokuchiet al 2011 | Japan English | IHC≥10% | 1999-2002 | 12629% | NR | 88/38 | stage I–IV | 73(2-135) | 2.2(0.99-4.9) | 0.053 | 7 |
| Zhanget al 2011 | China Chinese | IHC≥1+ | 2001-2008 | 8455.9% | 55(22-84) | 47/37 | stage II–IV | 11 | 1.33(0.71-2.5) | 0.37 | 7 |
| Atmacaet al 2012 | Germany English | IHC≥1+ | NR | 35757.4% | NR | 214/143 | stage IV | 18.2(3.3-44.1) | 0.91(0.66-1.16) | 0.464 | 8 |
| Terashimaet al 2012 | Japan English | IHC≥3+ | NR | 8299% | NR | 565/264 | stage II–III | 60 | 1.64(1.14-2.37) | 0.008 | 7 |
| Al-Moundhri et al 2012 | Oman English | IHC≥10% | 1995-2005 | 11513.9% | 59.2(21-90) | 72/43 | stage I–IV | 96 | 1.72(1.09-2.7) | 0.02 | 7 |
| Gaoet al 2013 | China English | IHC≥50% | 2000-2007 | 7857.7% | NR | 40/38 | stage I–IV | NR | 2.07(0.88-4.87) | 0.096 | 7 |
| Liet al 2013 | China Chinese | IHC≥2+ | 2006 | 16146% | 61(33-80) | 124/37 | stage I–IV | 39.6 | 1.01(0.55-1.85) | 0.974 | 7 |
| Kandelet al 2013 | France English | IHC≥2+ | 1999-2002 | 8216.3% | 67(38-95) | 58/24 | stage I–III | 40 | 1.68(0.82-3.46) | 0.158 | 7 |
| Aydinet al 2013 | Turkey English | IHC≥2+ | 2008-2011 | 3063.3% | 34-85 | 20/10 | stage II–IV | 12(2-25) | 0.36(0.1-1.23) | 0.118 | 7 |
| Kurokawaet al 2014 | Japan English | IHC≥10% | 2000-2006 | 15314.4% | 68(35-98) | 104/49 | stage I–IV | NR | 1.78(0.94-3.38) | 0.077 | 8 |
| Fuseet al 2014 | Japan English | IHC≥2+ | 2006-2010 | 29327% | ≥20Y | 201/92 | unresectable or recurrent | 58.4 | 1.12(0.86-1.46) | 0.401 | 7 |
| Tanget al 2014 | China English | IHC≥2+ | 2007-2010 | 12133.1% | NR | 85/36 | stage II–IV | NR | 1.41(0.73-2.74) | 0.306 | 7 |
| Nagatsumaet al 2014 | Japan English | IHC≥2+ | 2003-2007 | 95023.5% | 63(18-92) | 734/316 | stage I–IV | 60(1-120) | 0.58(0.39-0.87) | 0.007 | 7 |
| Paligaet al 2015 | Canada English | IHC≥2+ | 2002-2008 | 11315% | 64(30-94) | 81/32 | stage I–IV | 80(73-93) | 1.6(0.89-2.87) | 0.11 | 8 |
| Seoet al 2015 | Korea English | HC≥2+ | 2003-2010 | 87912.6% | NR | NR | stage I–IV | NR | 0.66(0.27-1.65) | 0.377 | 7 |
| Parket al 2016 | Korea English | IHC≥3+ | 2000-2003 | 93514.7% | 59(25-86) | 618/317 | stage I–III | NR | 0.92(0.69-1.22) | 0.57 | 7 |
* NOS, Newcastle-Ottawa Quality Assessment Scale; HR, hazard ratio; CI, confidence interval.